so where do we stand..

The trial results were similiar to those announced in July.There is a hint in the announcement under section 8--"Pharmacokinetic (PK) results suggest that subjects were not optimally dosed. Results show there was significant variability in the amount of XToll measured in the blood of patients. It is apparent that the existing formulation is not optimal for injection under the skin. Reformulation work will be required in advance of any future large-scale clinical trial".
What I have heard is that only 3% of Xtoll entered the bloodstream of patients and this is apparently quite a simple reformulation exercise to remedy.So if only 3% achieved the results we are seeing now-imagine what could be achieved!Lets get the new board in and get things moving.I will be at the Brisbane meeting tomorrow night to meet the new directors.